Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Dr. Terri Lewis, thought leader for opioid policy reform

There are many prominent researchers working behind the scenes to rectify erroneous opioid policies at the state and federal level. Among these silent researchers, Dr. Terri Lewis’s work rings the loudest.

She has redefined the very meaning of data in the opioid epidemic, conducting one of the largest behavioral surveys on opioid use and the experience of chronic pain.

Through her research, we now know of inherent biases within the data used in opioid risk stratification, and the implications of these biases on the lives of chronic pain patients across the country.

It is because of researchers like Dr. Terri Lewis that we understand the value of prescription opioids through the voices of people with lived experience.

To glean preliminary results from her ongoing survey, please select the link below:

https://drive.google.com/file/d/1lOjfEJZz8ZbebSE4O-u3rM8Ka4RD8fZI/view?usp=sharing

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!